In September 2026, Reuters reported that CVS Health’s Aetna in the USA would introduce a single medical prior-authorisation process for cancer treatment, replacing separate approvals for components such as chemotherapy, radiotherapy, imaging and some immunotherapies. The change began on 1 September for Medicaid members in eight US states and is scheduled to reach Aetna’s private and Medicare Advantage plans during the first half of 2027. Aetna says that providers